Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1111 to 1125 of 1422 results for social care

  1. Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies [ID1288]

    Discontinued [GID-TA10212]

  2. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued [GID-TA11041]

  3. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    In development [GID-TA10841] Expected publication date: TBC

  4. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development [GID-TA10696] Expected publication date: TBC

  5. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

  6. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued [GID-TA10318]

  7. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued [GID-TA10158]

  8. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued [GID-TA10338]

  9. Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

    Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma in adults.

  10. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued [GID-TA10418]

  11. Lifitegrast for treating dry eye disease [ID1229]

    Discontinued [GID-TA10196]

  12. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued [GID-TA10429]

  13. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued [GID-TA10254]

  14. Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]

    Discontinued [GID-TA10186]

  15. Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

    Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had pemetrexed and cisplatin.